大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病的保护作用

目的探讨阿托伐他汀(80 mg)联合水化对老年(年龄≥60岁)急诊冠状动脉介入术(PCI)术后造影剂肾病的保护作用。方法 92例患者随机分为大剂量强化治疗组、常规剂量治疗组、空白对照组,3组患者在水化治疗的基础上,大剂量强化治疗组:入院后口服阿托伐他汀80 mg,急诊PCI术后3 d内口服阿托伐他汀40 mg.d-1;常规剂量治疗组:入院后口服阿托伐他汀20 mg,急诊PCI术后3 d内口服阿托伐他汀20 mg.d-1;空白对照组:术前未给予他汀类药物。分别测定3组患者术后24,72 h的血肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)以及造影剂肾病的发生率。结果急诊PCI术后24 h与PCI术前相比,大剂量强化治疗组BUN,Scr的增加值较常规剂量治疗组小,差异有统计学意义(P<0.05)。急诊PCI术后72 h与PCI术前相比,大剂量强化治疗组BUN,Scr的增加值以及Ccr的下降值明显低于常规剂量治疗组(P<0.05)。结论大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病具有一定的保护作用。     

阿托伐他汀联合普罗布考改善对比剂急性肾损伤的临床观察

目的:观察术前联用不同剂量阿托伐他汀与普罗布考对对比剂急性肾损伤(CIAKI)的影响。方法:149例接受择期冠状动脉造影(CAG)或经皮冠状动脉支架植入术(PCI)的冠心病患者,随机分为标准剂量组46例,阿托伐他汀每晚顿服20mg及普罗布考250mg,3次/d;强化联合组47例,阿托伐他汀每晚顿服40mg及普罗布考250mg,3次/d,术前2h顿服阿托伐他汀40mg普罗布考500mg;强化剂量组56例,阿托伐他汀每晚顿服40mg,术前2h顿服阿托伐他汀40mg。所有患者均于术前和术后24h抽取静脉血检测尿素氮(BUN)、肌酐(Scr)、肾素全项,MDRD方法估算肾小球滤过率(eGFR)。结果:(1)与术前比较,标准剂量组术后Scr升高,eGFR下降,AngⅡ升高(P<0.05);强化联合组术后BUN和AngⅡ下降,强化剂量组术后BUN下降(P<0.05或P<0.01),Scr及eGFR差异无统计学意义。(2)强化联合组Scr下降值(△Scr)及△AngⅡ高于标准剂量组(P<0.05)。(3)对于肾功能轻中度损伤患者,强化联合组△Scr和△BUN高于其他2组(P<0.05)。结论:阿托伐他汀联合普罗布考强化或单用阿托伐他汀强化均可改善CIAKI,对于肾功能轻中度损伤患者,强化联合治疗改善作用显著。     

强化阿托伐他汀对高剂量造影剂致对比剂肾病的临床研究

目的:探讨和分析强化剂量阿托伐他汀对应用不同剂量非离子低渗造影剂碘帕醇患者肾功能的影响.方法:将择期行冠状动脉造影(CAG)和经皮冠状动脉介入术(PCI)患者200例,随机分为强化剂量阿托伐他汀治疗组(100例)和常规剂量阿托伐他汀治疗组(100例),在全部采用水化治疗基础上,强化组给予强化剂量阿托伐他汀口服(术前1 d 80 mg,术前2 h 40 mg),常规组给予常规剂量阿托伐他汀口服(术前1 d 20 mg).其中对进行单纯造影与造影后直接PCI术的患者根据造影剂用量的不同,分为≤120mL组和＞120 mL组,分别于术前、术后测定血清肌酐(Scr)、BUN及超敏C反应蛋白(hsCRP)等指标,按Cochcroft-Gault公式计算内生肌酐清除率(Ccr),并进行统计学分析.结果:与术前相比,术后常规剂量组和强化剂量组患者Scr、BUN水平均明显升高,Ccr均明显下降(P＜0.05);常规剂量组患者hsCRP水平升高(P＜0.05),而强化剂量组hsCRP水平变化相近(P＞0.05).强化剂量组的患者造影剂使用剂量的大小对肾功能无明显影响,≤120mL组和＞120mL组比较差异无统计学意义(P＞0.05),但常规剂量组肾功能差异具有统计学意义,表现为Scr、BUN及hsCRP水平≤120mL组较＞120mL组升高(P＜0.05),Ccr≤120mL组较＞120mL组下降(P＜0.05).常规剂量阿托伐他汀治疗组发生对比剂肾病(CIN)患者有12例,发生率为12％;＞120mL发生对比剂肾病患者有8例,发生率为14％.结论:术前强化剂量阿托伐他汀治疗可显著降低高剂量造影剂对肾功能的影响,减少对比剂肾病的发生.     

五苓散联合阿托伐他汀对急性心肌梗死择期PCI患者术后对比剂肾病发生率的影响

目的探究五苓散联合阿托伐他汀对急性心肌梗死择期经皮冠状动脉介入术(PCI)患者术后对比剂肾病发生率的影响。方法将110例急性心肌梗死择期行PCI患者随机分为2组,对照组55例给予阿托伐他汀治疗,研究组55例给予五苓散联合阿托伐他汀治疗,2组均术前3 d到术后3 d持续用药,比较2组术后对比剂肾病发生率,检测2组术前、术后24 h血清肌酐(Scr)、内生肌酐清除率(Ccr)以及α_1微球蛋白(α1-MG)水平,观察2组治疗期间不良反应发生情况。结果研究组对比剂肾病发生率显著低于对照组(P<0.05)。术后24 h研究组Scr、Ccr、α_1-MG水平与治疗前比较无明显变化(P>0.05);对照组Scr、α_1-MG水平显著高于术前及研究组,Ccr显著低于术前及研究组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论五苓散联合阿托伐他汀应用于急性心肌梗死择期PCI患者,可显著降低对比剂肾病发生率,保护患者肾功能,安全性高,值得临床推广应用。     

不同剂量阿托伐他汀对行经皮冠状动脉支架植入术治疗患者术后发生造影剂肾病的影响

目的 探讨不同剂量阿托伐他汀对行经皮冠状动脉支架植入术(PCI)患者术后发生造影剂肾病(CIN)的影响.方法 分析2016年3月至2017年3月在安徽医科大学第一附属医院行PCI的128例急性心肌梗死患者(AMI)的临床资料,采用随机序贯综合平衡法随机分为强化组(64例,术前给予阿托伐他汀80 mg·d-1)和常规组(64例,术前给予阿托伐他汀20 mg·d-1),比较不同剂量阿托伐他汀治疗后患者PCI术后肾小球滤过率(eGFR)、血清肌酐(SCr)、尿β2球蛋白、胱抑素C(Cys C)、肌酸激酶(CK)、天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)以及CIN发生率的变化.结果 强化组比常规组PCI术后3 d CK水平增高;术后3 d的CysC水平以及术后2、3 d的Scr水平降低,差异有统计学意义(P<0.05);强化组的术后CIN发生率低于常规组(P=0.03);两组eGFR、SCr、尿 β2球蛋白以及CK的不同时间水平间差异有统计学意义(均P<0.001).多元logistic回归结果显示年龄、高血压、心功能衰竭以及阿托伐他汀剂量为经PCI治疗的患者术后发生CIN的独立危险因素,其中强化组患者术后发生CIN的概率相比常规组患者降低32％(OR:0.68,95％CI:0.56～0.83,P<0.05).结论 大剂量的阿托伐他汀可降低AMI患者经PCI治疗后发生CIN的概率,可保护患者肾脏功能,值得临床推广应用.     

阿托伐他汀对卒中患者颈动脉支架置入术后对比剂肾病的预防效果研究

目的:探讨阿托伐他汀对脑卒中患者颈动脉支架置入术(carotid artery stenting,CAS)后对比剂肾病的预防效果。方法:选择天津市环湖医院神经科2015年10月至2018年12月间行CAS治疗的患者,采用随机数字表分组法分为对照组和观察组。对照组术后给予阿司匹林(100 mg·d~(-1)),氯吡格雷(75 mg·d~(-1))治疗。观察组在对照组基础上给予阿托伐他汀(40 mg·d~(-1))治疗。比较2组术前、术后1、3、5和7 d的Scr、BUN、Ccr、β_2-MG、ALB、hs-CRP指标变化,对比剂肾病及不良事件发生情况。结果:2组患者术前Scr、BUN、Ccr、β_2-MG、ALB、hs-CRP比较差异无统计学意义(P>0.05);对照组术后1、3、5和7 d的Scr、BUN、β_2-MG、ALB、hs-CRP高于术前,Ccr低于术前(P <0.05);观察组术后1、3、5和7 d的Scr、BUN高于术前(P <0.05),术后1、3、5和7 d Ccr、β_2-MG、ALB、hs-CRP与术前比较差异无统计学意义(P>0.05);观察组术后1、3、5和7 d Scr、BUN、β_2-MG、ALB、hs-CRP低于对照组,Ccr高于对照组(P<0.05)。观察组对比剂肾病发生率(7.50%)低于对照组(18.75%)(P<0.05)。结论:阿托伐他汀可减轻脑卒中患者CAS术后对比剂对肾功能的损伤,对对比剂肾病的预防效果好。     

Outcomes of rosuvastatin in preventing contrast-induced nephropathy in patients undergoing percuteous coronary intervention

目的 探讨强化瑞舒伐他汀治疗对经皮冠状动脉介入(PCI)术后对比剂肾病(CIN)的预防作用.方法 PCI手术患者182例均分为2组:A组PCI术前72 h应用瑞舒伐他汀20 mg(每晚睡前口服)强化治疗;B组给予瑞舒伐他汀10 mg(每晚睡前口服)常规治疗.观察术前、术后24、72 h的空腹血清肌酐(SCr)、血尿素氮(BUN)、肌酐清除率(Ccr)、高敏C反应蛋白(hs-CRP)变化,比较两组CIN的发生率.结果 与术前比较,术后24、72 h两组SCr、hs-CRP均明显升高(P＜0.05),Ccr明显下降(P＜0.05).术后24 h及72 h,A组SCr、hs-CRP低于B组(P＜0.05),A组Ccr高于B组(P＜0.05).A组CIN发生率低于B组(2.20％vs.8.79％)(P＜0.05).结论 PCI术前强化瑞舒伐他汀治疗可降低PCI术后CIN发生率.     

强化他汀治疗对急诊冠脉介入治疗术后对比剂肾病的预防作用

目的：探讨强化阿托伐他汀治疗对急诊经皮冠状动脉介入治疗（PCI）术后对比剂肾病（CIN）的预防作用。方法选择行急诊PCI 的急性ST段抬高型心肌梗死（STEMI）患者268例,随机分为常规组（n＝132）和强化组（n＝136）。常规组及强化组患者分别于PCI术前开始口服阿托伐他汀（20 mg/d及80 mg/d）,术后连续使用7 d（20 mg/d及60 mg/d）,之后以20 mg/d 维持治疗。观察两组患者术前、术后3 d血清肌酐（Scr）、内生肌酐（Ecr）及估算肾小球滤过率（eGFR）变化情况。结果强化组术后Scr、Ecr 水平及CIN发生率显著性低于常规组,而eGFR显著性高于常规组,差异具有统计学意义（P＜0.05）。强化组PCI术后30 d主要不良心血管事件（MACEs）发生率（7.4%）显著性低于常规组（15.2%）,差异具有统计学意义（χ2＝4.10,P＝0.043）。结论STEMI 患者急诊PCI术前强化给予阿托伐他汀治疗可以降低CIN的发生率,改善患者的预后。     

强化阿托伐他汀治疗对老年人冠心病介入治疗术后造影剂肾病的影响

目的 探讨强化剂量阿托伐他汀对老年冠心病(CHD)患者经皮冠状动脉介入治疗(PCI)术后造影剂肾病( CIN)的预防作用.方法 将100例年龄＞60岁的行冠脉介入治疗的CHD患者随机分为观察组和对照组,每组50例.在全部采用水化治疗基础上,观察组给予强化剂量阿托伐他汀,对照组给予常规剂量阿托伐他汀.术前、术后测定血清肌酐(Scr)、血β2-微球蛋白(β2-MG)、肝功能等指标,按Cochcroft-Gault公式计算内生肌酐清除率(Ccr);记录住院期间和随访期间30d内主要不良心脏事件(MACE)发生率及肝毒性和肌毒性发生情况.结果 术后第1、3天观察组Ccr显著高于对照组[(73.12±16.89)ml/min比(63.89±18.42)ml/min,P=0.036]、[(65.32±13.46) ml/min比(55.63±15.47) ml/min,P=0.021];术后第1、2、3d观察组β2-MG显著低于对照组[( 2.44±0.42) ml/min比(2.69±0.63) ml/min,P=0.009]、[(2.52±0.46) ml/min比(2.81±0.63) ml/min,P=0.011]、[(2.37±0.43) ml/min比(2.54±0.65) ml/min,P=0.021];观察组CIN发生率显著低于对照组(分别为6％和24％,P=0.012);随访30 d内,共14例(14％)患者发生MACE,其中观察组3例(6％),对照组11例(22％)(x2=5.316,P=0.021);两组均无肌毒性和肝毒性发生.结论 PCI术前服用强化剂量阿托伐他汀对老年患者CIN的发生可能有更好的预防作用,且较为安全.     

瑞舒伐他汀预防PCI术后对比剂肾病的效果

目的探讨强化瑞舒伐他汀治疗对经皮冠状动脉介入(PCI)术后对比剂肾病(CIN)的预防作用。方法 PCI手术患者182例均分为2组:A组PCI术前72h应用瑞舒伐他汀20mg(每晚睡前口服)强化治疗;B组给予瑞舒伐他汀10mg(每晚睡前口服)常规治疗。观察术前、术后24、72h的空腹血清肌酐(SCr)、血尿素氮(BUN)、肌酐清除率(Ccr)、高敏C反应蛋白(hs-CRP)变化,比较两组CIN的发生率。结果与术前比较,术后24、72h两组SCr、hs-CRP均明显升高(P<0.05),Ccr明显下降(P<0.05)。术后24h及72h,A组SCr、hs-CRP低于B组(P<0.05),A组Ccr高于B组(P<0.05)。A组CIN发生率低于B组(2.20%vs.8.79%)(P<0.05)。结论 PCI术前强化瑞舒伐他汀治疗可降低PCI术后CIN发生率。     

宝石能谱CT冠状动脉成像在冠心病诊断中的应用

目的 评价宝石能谱CT冠状动脉成像(CTA)在冠心病诊断中应用价值.方法 63例疑似冠心病分别接受CTA和冠状动脉造影检查,以冠状动脉造影结果为“金标准”对照,评估冠状动脉CTA检查的准确度.结果 冠状动脉CTA可以清晰显示冠状动脉狭窄病变,与冠状动脉造影相比,两者的符合率达96.0％.结论 CTA安全、简便和无创伤,对冠状动脉疾病具有较大的诊断价值.     

左冠状动脉主干狭窄的临床分析

目的探讨左主干狭窄的临床特点和治疗方法.方法分析左主干病变(狭窄≥50%)者和非左主干病变者临床资料.结果1 275例确诊的冠心病患者中,左主干狭窄74例(5.8%),非左主干病变180例(14.1%).左主干合并3支病变占66.2%,左主干病变组心绞痛发生率较非左主干病变组高.57例(77.0%)胸痛发作时心电图ST段下移≥0.2 mV.左主干并3支组与单纯左主干组比较心肌梗死发生率高(P＜0.05),左室射血分数低(P＜0.01).23例行CABG 1年内心绞痛症状消失或明显减轻,3例行无保护左主干直接支架术,术后半年心绞痛明显减轻.结论左主干狭窄者多合并其它冠脉病变,心绞痛严重.冠状动脉旁路移植术是最佳治疗手段.     

经皮冠状动脉介入治疗79例临床分析

目的探讨经皮冠状动脉介入治疗的可行性、安全性和成功率。方法选择该院2005年1月~2009年7月经皮股动脉穿刺冠状动脉腔内成形术（PTCA）及支架术79例患者为研究对象。结果A型病变支架术成功率100%（36/36）,B型病变成功率98.9%（88/89）,C型病变成功率95.3%（41/43）。1例分叉、弯曲、偏心性病变和2例慢性闭塞性病变（CTO）因指引导丝不能通过病变致手术失败,总成功率为98.2%。结论经皮冠状动脉介入治疗创伤小,恢复快,安全且成功率高。     

冠心病住院患者冠状动脉介入诊疗依从性的初步研究

目的探讨影响冠心病患者对冠状动脉介入诊疗的依从性的主要因素。方法回顾性分析2008年10月至2009年7月间我科住院的临床诊断为冠心病的505名患者,观察资费来源、冠心病亚型及年龄阶段三个不同因素对住院期间冠状动脉介入诊疗依从性的影响。结果随着年龄的增长,对冠状动脉介入的依从性逐步减低;军队医保组与自费组较社会医保组依从性较高;疾病类型对介入依从性影响则相对较小。结论在当前医疗保障体制下,心脏冠状动脉介入诊疗的依从性明显受到包括医疗资源保障程度、年龄阶段等多种因素的影响。     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.